MANAGEMENT OF PEPTIC-ULCER DISEASE

The period under review saw the landmark development of the publicatio n of the Helicobacter pylori genome. There were at least three attempt s at guiding the clinician with regard to selection of patients in nee d of therapy for H. pylori infection. Therapeutic strategies have evol ved and include proton-pump inhibitor-based combination therapies. The controversy regarding the pathogenic potential of H. pylori strains c ontinued, with no perfect marker being identified. The role of the org anism in NSAID-associated disease was investigated also, yielding inte resting results.